Angiocrine Bioscience, Inc., a biotechnology company, has developed the VeraVecTM cellular platform for amplifying stem and progenitor cells, in both human and mouse models, by recapitulating the proliferative stimulation of the in vivo vascular niche in vitro. The expansion capacity is on an unprecedented scale when compared to any other competing technology, and it is achieved without the requirement for costly mediate additives. This process can meet the needs of a broad range of therapeutic, diagnostic and research applications.
Historically, in vitro based endothelial cell cultures have not been able to take advantage of the properties maintained in vivo due to the need for a variety of non-physiologically relevant factors to sustain cell survival and proliferation. These additions are not necessarily pro-angiogenic, can be deleterious to the cells, and can complicate the interpretation of results from in vitro systems. VeraVec’s endothelial cells are no longer dependent on irreducibly complex additives typically used for endothelial cell cultures.
The VeraVec products consist of both Mouse and Human endothelial cells that adapt to cell culture in a variety of media formulations, including serum-free conditions in several of our products, and yet maintain the phenotypes and behaviors expected of primary cells. All endothelial cells are treated with our proprietary technology that enables the cells to be passaged usefully 3-5 as many times as their naïve counterparts while simultaneously offering a more consistent phenotype and maintenance of the endothelial cell fate. This innovative technology confers unique properties in that cells in culture will behave more consistently from passage to passage as they are now resistant to the phenotypic drift that has plagued vascular biology research for decades.
VeraVec endothelial cells are also an ideal platform for the culture and expansion of various adult stem cells, embryonic stem cells, and iPS lineages. This feeder layer is responsive and dynamic with the entirety of the endogenous growth factors available upon co-culture with the lineage of choice. No longer are researchers dependent on extraordinary means to propagate and study stem cells.
Angiocrine Bioscience’s proprietary technology now provides novel avenues of discovery in the fields of endothelial cell biology and stem cell expansion without the associated expense and labor.
« Go back